Desteklenen Projeler
Patent
-
2023 ANTİKANSER AKTİVİTEYE SAHİP YENİ VİSİNAL DİARİL HETEROSİKLİK BİLEŞİK TÜREVLERİ
-
2022 TW111113780-COMPOSITIONS AND METHODS FOR TREATING CANCER
-
2022 JP2022-527677-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS
-
2022 KR10-2022-7020047-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS
-
2022 CN 202080091759.9 (2022110200431050)-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS
-
2022 EP20888312.4-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS
-
2022 PCT/US2022/024263 (WO2022/221194 A1) COMPOSITIONS AND METHODS FOR TREATING CANCER
-
2022 US17/776,767-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS
-
2021 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-HongKong
-
2021 COMPOSITIONS AND METHODS FOR TREATING CANCER
-
2021 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-CN
-
2020 ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS (US/PCT)
-
2020 ANTİ-KANSER AJANI OLARAK KULLANILABİLECEK YENİ POTANSİYEL TACC3 İNHİBİTÖRÜ (BRP-OZG-264)
-
2020 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-JP
-
2020 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-US
-
2020 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-KR
-
2020 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-EP
-
2019 ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS